ARTICLE PDF (Українська)


blood pressure variability, cognitive impairment, brain ischemia

How to Cite



Goal. To review the literature on the problem of the influence of variability of blood pressure on the cognitive function of patients with dyscirculatory encephalopathy after suffering ischemic stroke on the background of hypertension.

Research Methods: Bibliosemantic, Comparative and Systemic Results. In the Recommendations of the European Society of Cardiologists / European Society for Hypertension (European Approach).

Society for Cardiology / European Society of Hypertension - ESC / ESH) 2018 for the treatment of hypertension emphasized that the study of cognitive function (CF) should be mandatory in the list of methods of examination of patients to detect the damage of target organs caused by hypertension, in order refinement of stratification of risk of cardiovascular events, namely stroke (Williams B. et al., 2018). Cognitive impairment in patients with cardiovascular disease is known to be one of the earliest and most sensitive indicators of cerebral vascular injury and is a consequence of chronic cerebral ischemia and / or recurrent acute cerebral circulation disorders. It is proved that the variability of blood pressure has a negative effect on cerebral circulation, is a predictor of chronic brain ischemia, which can result in the appearance or deepening of cognitive impairment. In the ASCOT study on the prognostic significance of variability in daily monitoring of blood pressure, intracutaneous variability, and long-term variability, it was found that visit-to-visit variability is a strong predictor of stroke and coronary events, not independent of the level.

Conclusions. Analysis of the literature on this problem has shown the negative effect of blood pressure variability on the course of chronic brain ischemia, which exacerbates cognitive and emotional-volitional disorders in patients with hypertensive dyscirculatory encephalopathy. The peculiarities of the effect of blood pressure variability on CF in patients with brain stroke are poorly understood and need further investigation.
ARTICLE PDF (Українська)


Khomazyuk T.A., Krotova V. Yu. (2019). Risk factors for cognitive impairment in arterial hypertension. Ukrainian Medical Journal. 2 (2) (130) III / IV.

Sirenko Yu. M. (2004). Medicinal prophylaxis of stroke in patients with arterial hypertension. Medicines of Ukraine., 12, 7–12.

Feigin V. L. et al. (2016). Global Stroke and Risk Factors in 188 countries, during 1990 - 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 15, 9, 913 - 924.

Gorbunov, V.M. (2012). Modern ideas about the variability of blood pressure. Rational pharmacotherapy in cardiology, 8 (6), 810–818.

Kang, J., Ko Y., Park J. H., Kim W.-J., Jang M. S., Yang M. H. et. al. (2012). Effect of blood pressure on 3-month functional outcome in the subacute stage of ischemic stroke . Neurology, 79, 20, 2018–2024. doi: 10.1212 / wnl.0b013e3182749eb8

Webb A. J., Fischer U., Mehta Z., Rothwell P. M. (2010). Effects of antihypertensive drug class on interindividual variation in blood pressure and stroke risk: a systematic review and meta-analysis. The Lancet, 375, 9718, 906-915. doi: 10.1016 / s0140-673

Damulin I.V., Parfenov V.A., Skoromets A.A., Yahno N.N. (2001). Nervous system diseases -stema Manual for doctors / Ed. N.N. Jahno., D.R. Stulman. M., 1, 231-302.

Damulin I.V. (2002). Alzheimer's disease and vascular dementia . Ed. N.N. Riding. M., 7 - 47.

Burns A., Zaudig M. (2002). Mild cognitive impairment in older people. Lancet, 360, 1963 - 1965. 6 (10) 60235-8.

Stevens L.A., Coresh J., Greene T., Levey A.S. (2006). Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med, 354, 2473–2483.

Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G., )(2005). Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int., 67, 2089–2100.

Shlipak M.G., Katz R., Sarnak M.J., Fried L.F., Newman A.B., Stehman-Breen C., Seliger S.L., Kestenbaum B., Psaty B., Tracy R.P., Siscovick D.S. (2006). Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med., 145, 237–246.

Culleton B.F., Larson M.G., Wilson P.W., Evans J.C., Parfrey P.S., Levy D. (1999). Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int., 56, 2214-2219.

Parving H.H. (1996). Initiation and progression of diabetic nephropathy. N Engl J Med., 335, 1682–1683.

Ruilope L.M., Rodicio J.L. (1993). Clinical relevance of proteinuria and micro-albuminuria. Curr Opin Nephrol Hypertens., 2, 962–967.

Redon J., Williams B. (2002). Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens, 20, 353–355.

Arnlov J., Evans J.C., Meigs J.B., Wang T.J., Fox C.S., Levy D., Benjamin E.J., D’Agostino R.B., Vasan R.S. (2005). Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation, 112? 969–975.

Zanchetti A., Hansson L., Dahlof B., Elmfeldt D., Kjeldsen S., Kolloch R., Larochelle P., McInnes G.T., Mallion J.M., Ruilope L., Wedel H. (2001). Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens.,19, 1149–1159.

Ruilope L.M., Salvetti A., Jamerson K., Hansson L., Warnold I., Wedel H., Zanchetti A. (2001). Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephro, 12, 218–2265.

Mancia G., Parati G., Pomidossi G., Grassi G., Casadei R., Zanchetti A. (1987). Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension, 9. 209–215.

Dimmitt S.B., West J.N., Eames S.M., Gibson J.M., Gosling P., Littler W.A. (1989). Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet, 1 , 1103–1106.

Kilander L., Nyman H., Boberg M., Hansson L., Lithell H. (1998). Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension, 31, 780–786.

Forette F., Seux M.L., Staessen J.A. Thijs L., Babarskiene M.R., Babeanu S., Bossini A., (2002). Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med.,162, 2046–2052.

Coope J., Warrender T.S. (1986). Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J., 293, 1145–1151.

He F. J., Markandu N. D., MacGregor G.A. (2001). Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. Hypertension, 38, 321–325.

Grassi G., Dell’Oro R., Seravalle G., Foglia G., Quarti Trevano F, Mancia G. (2002). Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation, 106, 1957–1961.

Sacks F. M., Svetkey L. P, Vollmer W. M., Appel L. J., Bray G.A., Harsha D., Obarzanek E., Conlin P.R., Miller E.R. (2001). DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med., 344. 3–10.

Morris M.C., Sacks F., Rosner B. (1993). Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation, 88, 523–533.

Geleijnse J. M., Giltay E.J., Grobbee D.E., Donders A.R., Kok F.J. (2002). Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens, 20, 493–1499.

Appel L.J., Miller E.R. Seidler A.J., Whelton P.K. (1993). Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med., 153, 1429– 1438.

Hypertension (2017). Clinical guidance. State Expert Center of the Ministry of Health of Ukraine, Association of Cardiologists of Ukraine.

Kovalenko A.E., Kravchenko A.M., Litvin O.V., Ovodyuk N.M., Cherny T.V., Zakrutko L.I. (2017). Features of management of patients with hypertensive dyscirculatory encephalopathy and concomitant diseases in ambulatory conditions: Methodical recommendations. Kyiv. 20.

Kovalenko O.E., Lytvyn O.V. (2017). Chronic brain ischemia in patients with arterial hypertension and thyroid dysfunction. International Endocrinology Journal., 13, 1, 120-127.

Kovalenko O.E. (2006). Assessment of heart rate variability in vertebral-basilar disorders associated with the cervicovertebral factor. Medical journal, 3 (53), V-VI, 133-137.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.